Skip to Main Content

As the pharmaceutical industry faces pointed criticism over its patent practices, an effort appears to be under way to push back and challenge one of its leading critics in hopes of changing the narrative about patents and their role in prescription drug pricing.

The focus is on a nonprofit called the Initiative for Medicines, Access & Knowledge, or I-MAK, which has published several papers over the last few years criticizing drug makers for pursuing patents that may profitably extend the marketability of their medicines, but without necessarily adding any new, substantive value.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment